Analysts Viewpoint
Analysts review Summit Therapeutics Inc’s rating
Taking this into account, Citigroup upgraded its Summit Therapeutics Inc [SMMT] rating to a Buy from a a Neutral in
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.